When is PGT-M recommended for a thalassaemia carrier?

A carrier usually has one altered haemoglobin gene and may have no symptoms or mild blood-count changes. The reproductive implications depend on the exact variant and the other partner’s result. A carrier screen alone does not show which embryos are affected, so confirmatory genetic testing and counselling are needed.

PGT-M is a targeted test for a specified gene condition. The laboratory needs accurate family information to design the test, and the fertility team will explain embryo biopsy, result categories, storage, and transfer planning.

Ask for testing of both partners if this has not been completed, and take the written reports to a genetics appointment. Discuss the inheritance pattern, possible reproductive options, and whether PGT-M is technically suitable. Ask whether prenatal diagnostic testing would still be advised after transfer.

Your clinician can also review blood counts and iron studies when appropriate, because thalassaemia trait can resemble iron deficiency but is managed differently. Do not start iron supplements for a low blood count without clinical advice.

Seek prompt care for chest pain, severe breathlessness, fainting, marked weakness, or heavy bleeding during pregnancy or fertility treatment. A carrier result itself is not an emergency, but new or severe symptoms deserve assessment.

Which thalassaemia variant do we carry? Has the other partner been tested? Can PGT-M target our result, and what pregnancy testing is recommended after transfer?